Metagenome sequencing of fecal specimens from the patients before and after the administration of study drugs of RBX2660 and placebo

In this study, we explored the effect of a microbiota-based drug RBX2660, a suspension of healthy donor microbiota, on the gut microbiome and resistome of recipients treated for rCDI. rCDI patients received either a placebo (control group), one dose, or two doses of RBX2660. We demonstrate considerable shifts of taxonomic and resistome structures in placebo patients by RBX2660.